A Phase I placebo-controlled Study of PepGNP-ChikV in Healthy Volunteers

• Research type

  Research Study

• Full title

  A Phase I, dose-escalation, randomized, single-blind, placebo-controlled trial to evaluate the safety, reactogenicity, and immunogenicity of PepGNP-ChikV, a synthetic nanoparticle-based T cell next-generational vaccine against chikungunya in healthy adults

• IRAS ID

  1013539

• Contact name

  BRADLEY NORTON

• Contact email

  info@gyldenpharma.com

• Sponsor organisation

  GYLDEN PHARMA LIMITED

• Research summary

  This study is testing a new vaccine developed by a company called Gylden Pharma Limited. It is a new type of vaccine designed to help your immune system fight Chikungunya virus. It uses tiny particles and is given just under the skin using a small needle, similar to the way a mosquito bites. This is the first time this vaccine is being tested in humans. It is planned that a total of 40 volunteers will participate in this study.

• REC name

  London - Riverside Research Ethics Committee

• REC reference

  26/LO/0179

• Date of REC Opinion

  1 May 2026

• REC opinion

  Further Information Favourable Opinion